Trials / Completed
CompletedNCT04535063
Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determinate feasibility, safety and outcome with convalescent plasma in patients with severe COVID-19 penumonia
Detailed description
COVID-19 convalescent plasma will be infused to patients with severe COVID-19 pneumonia to determine feasibility, safety and clinical outcome efficacy by survival at-28 days. Data will be compared with match control arm patients without plasma infusion
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVID19 convalescent plasma infusion | intravenous infusion of 300-600 mL of convalescent plasma with an antibody title more than 3 according to chemiluminescent microparticle immunoassay (Architect Plus Abbott) |
Timeline
- Start date
- 2020-04-18
- Primary completion
- 2020-12-30
- Completion
- 2021-02-25
- First posted
- 2020-09-01
- Last updated
- 2022-07-19
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04535063. Inclusion in this directory is not an endorsement.